These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 23104988)

  • 1. Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma.
    Chand D; Yamazaki Y; Ruuth K; Schönherr C; Martinsson T; Kogner P; Attiyeh EF; Maris J; Morozova O; Marra MA; Ohira M; Nakagawara A; Sandström PE; Palmer RH; Hallberg B
    Dis Model Mech; 2013 Mar; 6(2):373-82. PubMed ID: 23104988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.
    Schönherr C; Ruuth K; Yamazaki Y; Eriksson T; Christensen J; Palmer RH; Hallberg B
    Biochem J; 2011 Dec; 440(3):405-13. PubMed ID: 21838707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.
    Bresler SC; Wood AC; Haglund EA; Courtright J; Belcastro LT; Plegaria JS; Cole K; Toporovskaya Y; Zhao H; Carpenter EL; Christensen JG; Maris JM; Lemmon MA; Mossé YP
    Sci Transl Med; 2011 Nov; 3(108):108ra114. PubMed ID: 22072639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN.
    Guan J; Tucker ER; Wan H; Chand D; Danielson LS; Ruuth K; El Wakil A; Witek B; Jamin Y; Umapathy G; Robinson SP; Johnson TW; Smeal T; Martinsson T; Chesler L; Palmer RH; Hallberg B
    Dis Model Mech; 2016 Sep; 9(9):941-52. PubMed ID: 27483357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.
    Schönherr C; Ruuth K; Kamaraj S; Wang CL; Yang HL; Combaret V; Djos A; Martinsson T; Christensen JG; Palmer RH; Hallberg B
    Oncogene; 2012 Dec; 31(50):5193-200. PubMed ID: 22286764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells.
    Cervantes-Madrid D; Szydzik J; Lind DE; Borenäs M; Bemark M; Cui J; Palmer RH; Hallberg B
    Sci Rep; 2019 Dec; 9(1):19353. PubMed ID: 31852910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The R1275Q neuroblastoma mutant and certain ATP-competitive inhibitors stabilize alternative activation loop conformations of anaplastic lymphoma kinase.
    Epstein LF; Chen H; Emkey R; Whittington DA
    J Biol Chem; 2012 Oct; 287(44):37447-57. PubMed ID: 22932897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.
    Moore NF; Azarova AM; Bhatnagar N; Ross KN; Drake LE; Frumm S; Liu QS; Christie AL; Sanda T; Chesler L; Kung AL; Gray NS; Stegmaier K; George RE
    Oncotarget; 2014 Sep; 5(18):8737-49. PubMed ID: 25228590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.
    Infarinato NR; Park JH; Krytska K; Ryles HT; Sano R; Szigety KM; Li Y; Zou HY; Lee NV; Smeal T; Lemmon MA; Mossé YP
    Cancer Discov; 2016 Jan; 6(1):96-107. PubMed ID: 26554404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.
    Lovisa F; Cozza G; Cristiani A; Cuzzolin A; Albiero A; Mussolin L; Pillon M; Moro S; Basso G; Rosolen A; Bonvini P
    PLoS One; 2015; 10(4):e0121378. PubMed ID: 25874976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.
    Bresler SC; Weiser DA; Huwe PJ; Park JH; Krytska K; Ryles H; Laudenslager M; Rappaport EF; Wood AC; McGrady PW; Hogarty MD; London WB; Radhakrishnan R; Lemmon MA; Mossé YP
    Cancer Cell; 2014 Nov; 26(5):682-94. PubMed ID: 25517749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.
    Wang Y; Wang L; Guan S; Cao W; Wang H; Chen Z; Zhao Y; Yu Y; Zhang H; Pang JC; Huang SL; Akiyama Y; Yang Y; Sun W; Xu X; Shi Y; Zhang H; Kim ES; Muscal JA; Lu F; Yang J
    Sci Rep; 2016 Jan; 6():19423. PubMed ID: 26786851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells.
    Sattu K; Hochgräfe F; Wu J; Umapathy G; Schönherr C; Ruuth K; Chand D; Witek B; Fuchs J; Li PK; Hugosson F; Daly RJ; Palmer RH; Hallberg B
    FEBS J; 2013 Nov; 280(21):5269-82. PubMed ID: 23889739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT.
    Debruyne DN; Bhatnagar N; Sharma B; Luther W; Moore NF; Cheung NK; Gray NS; George RE
    Oncogene; 2016 Jul; 35(28):3681-91. PubMed ID: 26616860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
    Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
    Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.
    Sasaki T; Okuda K; Zheng W; Butrynski J; Capelletti M; Wang L; Gray NS; Wilner K; Christensen JG; Demetri G; Shapiro GI; Rodig SJ; Eck MJ; Jänne PA
    Cancer Res; 2010 Dec; 70(24):10038-43. PubMed ID: 21030459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
    Lu J; Guan S; Zhao Y; Yu Y; Woodfield SE; Zhang H; Yang KL; Bieerkehazhi S; Qi L; Li X; Gu J; Xu X; Jin J; Muscal JA; Yang T; Xu GT; Yang J
    Cancer Lett; 2017 Aug; 400():61-68. PubMed ID: 28455243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
    Doebele RC; Pilling AB; Aisner DL; Kutateladze TG; Le AT; Weickhardt AJ; Kondo KL; Linderman DJ; Heasley LE; Franklin WA; Varella-Garcia M; Camidge DR
    Clin Cancer Res; 2012 Mar; 18(5):1472-82. PubMed ID: 22235099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse.
    Chen L; Humphreys A; Turnbull L; Bellini A; Schleiermacher G; Salwen H; Cohn SL; Bown N; Tweddle DA
    Oncotarget; 2016 Dec; 7(52):87301-87311. PubMed ID: 27888620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma.
    Carpenter EL; Haglund EA; Mace EM; Deng D; Martinez D; Wood AC; Chow AK; Weiser DA; Belcastro LT; Winter C; Bresler SC; Vigny M; Mazot P; Asgharzadeh S; Seeger RC; Zhao H; Guo R; Christensen JG; Orange JS; Pawel BR; Lemmon MA; Mossé YP
    Oncogene; 2012 Nov; 31(46):4859-67. PubMed ID: 22266870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.